Physician profile
Anish A Patel
NPI 1649476466
$1,318,436.31
in general payments reported to CMS, 2019-2025
30 companies · $430K in 2025
The $430K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $21K · 2021: $101K · 2022: $219K · 2023: $150K · 2024: $307K · 2025: $430K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $712K · Travel and Lodging: $138K · Food and Beverage: $21K · Consulting Fee: $15K · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $712,271.63 |
| Travel and Lodging | $137,964.61 |
| Food and Beverage | $21,467.36 |
| Consulting Fee | $14,825.00 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $381,024.70 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $301,087.32 | 2023-2025 | Tremfya, Stelara, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $180,410.25 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $149,891.31 | 2022-2025 | Omvoh, Mounjaro |
| Abbvie INC. | $102,938.06 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $90,519.24 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $59,604.89 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $27,598.09 | 2019-2021 | |
| Pfizer INC. | $14,918.28 | 2020-2024 | |
| Celgene Corporation | $5,642.20 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $2,516.31 | 2019-2020 | |
| Boston Scientific Corporation | $300.20 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $299.97 | 2023-2024 | Dupixent |
| Laborie Medical Technologies Corp. | $209.90 | 2023 | |
| Medtronic, INC. | $169.79 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $166.96 | 2023-2025 | Vio3apc3, Erbe Vio3 Apc3 |
| Madrigal Pharmaceuticals | $151.06 | 2025 | Rezdiffra |
| Calyxo, INC. | $145.38 | 2025 | Cvac Aspiration System |
| Olympus America INC. | $139.29 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $124.98 | 2025 | Iqirvo |
| Shire North American Group INC | $122.60 | 2019 | |
| Genzyme Corporation | $114.05 | 2023-2024 | |
| American Regent | $109.12 | 2019 | |
| Covidien Lp | $80.67 | 2019 | |
| Fresenius Kabi USA, LLC | $53.42 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $26.62 | 2019 | |
| Ironwood Pharmaceuticals, INC | $26.39 | 2024 | |
| Merck Sharp & Dohme LLC | $24.10 | 2024 | |
| Qol Medical, LLC | $21.16 | 2024 | Sucraid |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.